“NOVARTIS” MUST RETURN AROUND A MILLION RUBLES TO THE STATE FOR ABUSING DOMINANCE

The supplier of “Tyverb” is held administratively liable for violating the antimonopoly law

On 9 April 2018, “Novartis Pharma” Ltd. is held administratively liable for selling medicine with “Tyverb” trade name (“Lapatinib” International Non-Proprietary Name) in Russia at a monopolistically high price.

The violator of the antimonopoly law is imposed an administrative fine: 912,500 RUB.

Earlier FAS revealed that in January 2016 “Novartis Pharma” Ltd., which has the dominant market position, fixed and maintained the monopolistically high price for “Tyverb”, which violated Part 1 Article 10 of the Federal Law “On Protection of Competition” and infringing the interests of consumers at large.

Maxim Degtyaryov, Deputy Head of FAS Department for Control over Social Sphere and Trade pointed out: “In the course of the investigation, the antimonopoly body revealed that in 2016 “Novartis Pharma” Ltd. introduced a “new system of discounts and bonuses”, which, ironically, led to increasing the drug price. As a result of such manipulations with pricing, the violator must pay the fine and reduce the drug price in accordance with the injunction”.